Wockhardt LimitedNSE: WOCKPHARMA

Press Release Oct 07 2024

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

The drug is designed for outpatient treatment of complicated urinary tract infections and complicated intra-abdominal infections caused by multi-drug resistant pathogens. The Phase I study demonstrated a promising safety profile, with no serious adverse events reported, paving the way for further clinical trials.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Wockhardt Limited has informed the Exchange regarding a press release dated October 07, 2024, titled "Wockhardt's another breakthrough antibiotic: once-a-day β-lactam enhancer, WCK 6777 (Ertapenem/Zidebactam) with unique out-patient treatment advantage granted Fast Track designation by US FDA and successfully completes Phase I study conducted by National Institutes of Health, US".

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases